Kiniksa Entered into a Global License Agreement with Genentech to Develop and Commercialize Vixarelimab for Fibrosis
Shots:
- Kiniksa to receive $100M up front & near-term fees and is eligible to receive ~$600M in clinical, regulatory & sales-based milestones alongK with royalties & is currently planning to expand ARCALYST cardiovascular franchise
- Genentech to get the rights to develop & commercialize vixarelimab & will focus on the development of vixarelimab, a human mAb targeting OSMRβ in fibrosis where OSM-mediated pathogenesis is used for the intervention in multiple fibrotic indications
- The patient enrolment has been completed for the P-IIb clinical trial of vixarelimab in prurigo nodularis. Kiniksa plans to complete the trial but will stop disclosing information in H2’22
Ref: GlobeNewswire | Image: Kiniksa
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
